Skip to main content
SpringerLink
Log in

Treatment of Glioblastoma with Bevacizumab

Has a New Standard Therapy been Defined?

  • Editorial
  • Published:
CNS Drugs Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Genentech. FDA grants accelerated approval of Avastin for brain cancer (glioblastoma) that has progressed following prior therapy [online]. Available from URL: http://www.gene.com/gene/news/press-releases/display.do?method=detail&id=12087 [Accessed 2009 Nov 20]

  2. Lai A, Tran A, Nghiemphu PL, et al. Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J Clin Oncol 2010; 29(2): 142–8

    Article  PubMed  Google Scholar 

  3. Vredenburgh JJ, Desjardins A, Reardon DA, et al. The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide and irinotecan for newly diagnosed glioblastoma. Cancer Res 2011; 17(12): 4119–24

    Article  CAS  Google Scholar 

  4. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990; 82: 4–6

    Article  PubMed  CAS  Google Scholar 

  5. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9: 669–76

    Article  PubMed  CAS  Google Scholar 

  6. Morabito A, De Maio E, Di Maio M, et al. Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: current status and future directions. Oncologist 2006; 11: 753–64

    Article  PubMed  CAS  Google Scholar 

  7. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000; 407: 249–57

    Article  PubMed  CAS  Google Scholar 

  8. Chamberlain MC. Emerging clinical principles on the use of bevacizumab in the treatment of malignant gliomas. Cancer 2010; 116(17): 3988–99

    Article  PubMed  CAS  Google Scholar 

  9. Takano S, Yoshii Y, Kondo S, et al. Concentration of vascular endothelial growth factor in the serum and tumor tissue of brain tumor patients. Cancer Res 1996; 56: 2185–90

    PubMed  CAS  Google Scholar 

  10. Chi A, Norden AD, Wen PY. Inhibition of angiogenesis and invasion in malignant gliomas. Expert Rev Anticancer Ther 2007; 7: 1537–60

    Article  PubMed  CAS  Google Scholar 

  11. Sathornsumetee S, Rich JN. Antiangiogenic therapy in malignant glioma: promise and challenge. Curr Pharm Des 2007; 13: 3545–58

    Article  PubMed  CAS  Google Scholar 

  12. Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009; 27: 4733–40

    Article  PubMed  CAS  Google Scholar 

  13. Kreisl TN, Kim L, Moore K, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 2009; 27: 740–5

    Article  PubMed  CAS  Google Scholar 

  14. Raizer JJ, Grimm S, Chamberlain MC, et al. A phase II trial of single agent bevacizumab given in an every 3-week schedule for patients with recurrent high-grade gliomas. Cancer 2010; 116(22): 5297–305

    Article  PubMed  CAS  Google Scholar 

  15. Stark-Vance V. Bevacizumab and CPT-11 in the treatment of relapsed malignant glioma [abstract]. Neuro Oncol 2005; 7(3): 369

    Google Scholar 

  16. Wick W, Puduvalli VK, Chamberlain MC, et al. Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J Clin Oncol 2010; 28: 1168–74

    Article  PubMed  CAS  Google Scholar 

  17. Batchelor TT, Mulholland P, Neyns B, et al. The efficacy of cediranib as monotherapy and in combination with lomustine alone in patients with recurrent glioblastoma: a phase III randomized study. Neuro Oncol 2010; 12 Suppl. 4: iv69–78

    Article  Google Scholar 

  18. Grossman SA, Ye X, Piantadosi S, et al. Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States. Clin Cancer Res 2010; 16(8): 2443–9

    Article  PubMed  CAS  Google Scholar 

  19. Gilbert M. RTOG 0525: a randomized phase III trial comparing standard adjuvant temozolomide with a dose dense schedule in newly diagnosed glioblastoma [abstract no. 2006]. J Clin Oncol 2011; 29(15S): 141s

    Google Scholar 

  20. Chinot O. AVAglio: a phase III trial of bevacizumab added to standard radiotherapy and temozolomide in patients with newly diagnosed glioblastoma [abstract no. TPS 136]. J Clin Oncol 2011; 29(15S): 16s

    Google Scholar 

  21. Levin VA, Bidaut L, Hou P, et al. Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system. Int J Radiat Oncol Biol Phys 2011 Apr 1; 79(5): 1487–95

    Article  PubMed  CAS  Google Scholar 

  22. Nghiemphu PL, Liu W, Lee Y, et al. Bevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience. Neurology 2009; 72(14): 1217–22

    Article  PubMed  CAS  Google Scholar 

  23. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987–96

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

The editorial assistance of Sharon Larsson is appreciated and recognized. The author serves on the advisory board and speaker’s bureau for Genentech/Roche; however, no funding or support was provided for the preparation of this manuscript.

Author information

Authors and Affiliations

  1. Fred Hutchison Cancer Center, Seattle Cancer Care Alliance, University of Washington, 825 Eastlake Ave E, POB 19023, Seattle, WA, MS G4940, 98109, USA

    Marc C. Chamberlain (MD)

Authors
  1. Marc C. Chamberlain
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marc C. Chamberlain.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chamberlain, M.C. Treatment of Glioblastoma with Bevacizumab. CNS Drugs 25, 815–818 (2011). https://doi.org/10.2165/11587880-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11587880-000000000-00000

Search

Navigation